Uric

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uric

What is Uric? Defining the Therapeutic Entity

Property Description
Active ingredient Allopurinol
Form Oral tablet
Pharmacological class Uricostatic Agent
General purpose Reduction of serum uric acid levels
Origin Synthetic compound

1. Core Identity: The Uricostatic Agent Allopurinol

Uric is a prescription-only medicine whose active ingredient is Allopurinol, classifying it as a uricostatic agent within the broader field of chronic metabolic management. This drug is supplied as an oral formulation, specifically a tablet, which is its typical dosage form.

The core identity of Allopurinol is defined by its origin as a synthetic compound known chemically as a purine analogue. This structural classification is critical to its function, distinguishing it from agents that operate via different mechanisms, such as increasing uric acid excretion. Allopurinol serves as a foundational approach to managing hyperuricemia. Uric is one of several available formulations of allopurinol, all sharing this core composition and mechanism.


2. Understanding the General Purpose of Uric

the general purpose of Uric is to address the underlying metabolic issue of hyperuricemia—the excess concentration of uric acid in the bloodstream—by preventing its overproduction. The medicine achieves this through its function as a potent xanthine oxidase inhibitor, targeting the specific enzyme responsible for synthesizing uric acid.

By inhibiting xanthine oxidase, the medicine lowers the total amount of uric acid the body creates, representing a strategy of source reduction. The use of allopurinol is associated with lowering serum urate concentrations in patients. This action establishes Uric as a maintenance therapy drug, designed not to address acute symptoms, but rather to sustain normal metabolic function long-term by consistently limiting the concentration of this metabolic byproduct in the body's systems.

Regulatory References

  1. Allopurinol: MedlinePlus Drug Information

What side effects are possible with Uric?

Possible Side Effects and Safety Information

The safety profile of Uric, whose active ingredient is allopurinol, is documented in regulatory sources based on observed adverse reactions and specific risk factors. Adverse reactions are classified by frequency, with many grouped by the physiological system affected.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common Skin rash (maculopapular), an initial increase in acute gout attacks (flares) during therapy initiation, and increased blood TSH (with long-term use).
Uncommon Hypersensitivity reactions (generalized), vomiting, nausea, and abnormal liver function tests.
Rare Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and hepatitis.
Very Rare Serious blood disorders such as aplastic anaemia, agranulocytosis, and necrotizing vasculitis.

Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes the risk of Severe Cutaneous Adverse Reactions (SCARs), including SJS, TEN, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which are considered serious and potentially fatal. The regulatory standard requires immediate and permanent discontinuation of allopurinol at the first sign of a skin rash or other indication of hypersensitivity. Rechallenge is strictly contraindicated following a previous severe systemic reaction.


Population-Specific Risk Factors

The safety profile notes increased risks for specific populations. Patients with impaired renal function are known to have a higher risk of adverse reactions, including severe hypersensitivity. Additionally, individuals carrying the *HLA-B58:01 allele** (notably those of Han Chinese, Korean, or Thai descent) have a significantly higher documented risk of developing SJS/TEN.

Overdose and Emergency Response

The official regulatory documentation for Uric (Allopurinol) defines the overdose profile by its potential clinical manifestations and the required immediate emergency response. Documented presentations of overdose exposure include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, along with neurological effects such as dizziness.

When an overdose is suspected or known, regulatory authorities mandate that an individual seek immediate medical attention. This involves contacting emergency services or calling a certified Poison Control center without delay.

The documented management procedures center on general supportive measures and achieving adequate hydration. This procedure is intended to maintain optimum diuresis, which assists the body in facilitating the excretion of the drug and its metabolites. There is no specific antidote known for an allopurinol overdose.

A key physiological risk detailed in official labeling is that massive absorption can result in considerable inhibition of xanthine oxidase activity. This effect poses a specific risk for untoward complications in patients concurrently taking medications such as 6-mercaptopurine or azathioprine. Furthermore, the management context includes a note that the half-life of the active metabolite is greatly prolonged in the presence of renal impairment, a critical factor considered during observation.

Therapeutic Uses of Uric

Uric is utilized to help manage the levels of uric acid in the body, primarily for individuals diagnosed with hyperuricemia. Managing these levels is essential as they can contribute to joint-related issues. The medication assists in addressing several key concerns, including supporting the reduction in the frequency of acute gout flares, helping to alleviate persistent joint discomfort, and supporting the prevention of uric acid crystal buildup that can form deposits called tophi.

Common clinical scenarios of use include the long-term care of chronic gout and providing support during periods of elevated uric acid levels. The core benefit for the patient is the ability to support joint comfort and mobility over time through consistent uric acid management.

Quick Fact: Relief for Joint Discomfort

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who can and cannot use Uric?

The population eligibility for Uric (Allopurinol) is strictly determined by governmental regulatory labeling, defining groups for whom use is permitted, restricted, or absolutely prohibited.

Eligibility Status Population Group Regulatory Stance
Contraindicated Patients with known hypersensitivity or a history of a severe reaction to Allopurinol. Prohibited
Standard Use Adults with gout or hyperuricemia secondary to cancer treatment. Allowed
Restricted Use Patients with renal or hepatic impairment. Conditional Use
Restricted Use Women who are pregnant or breastfeeding. Not Recommended
Limited Use Pediatric patients (Children/Adolescents). Rarely Indicated

Use is not recommended for the treatment of asymptomatic hyperuricemia (high uric acid levels without symptoms). Furthermore, use is generally restricted in certain high-risk populations, such as those carrying the *HLA-B58:01 allele**. Pediatric use is typically reserved only for specific conditions like hyperuricemia related to malignancy or enzyme disorders. Patients with impaired organ function, such as kidney or liver problems, require close assessment as their eligibility depends on the severity of the impairment, often necessitating conditional use.

What should I know about interactions with other medicines?

Uric (Allopurinol) has officially documented interaction patterns that regulate its co-administration with other medicines and substances. Regulatory documents state that the uricolytic agent Pegloticase is formally contraindicated and must not be initiated or continued during Allopurinol therapy.

A primary interaction involves the inhibition of metabolism for certain cytotoxic drugs, significantly increasing their exposure. Co-administration with Mercaptopurine and Azathioprine requires a mandatory dose reduction of the cytotoxic agent, typically to one-quarter of the usual dose, to prevent potentially fatal accumulation.

Other interactions involve pharmacodynamic risk enhancement. The use of Uric alongside Thiazide Diuretics is associated with an increased risk of severe hypersensitivity reactions, a risk particularly heightened when concurrent decreased renal function is present. Similarly, co-administration with Ampicillin or Amoxicillin carries a documented risk of skin rash. Uric may also increase the plasma concentrations of Cyclosporine and enhance the effects of Coumarin Anticoagulants.

Furthermore, co-administration with Uricosuric agents such as Probenecid accelerates the clearance of Allopurinol’s active metabolite, which may reduce its therapeutic activity. Timing separation is required for some products; a minimum 3-hour gap is necessary between Uric and Aluminum Hydroxide administration to ensure proper absorption.

Mechanism of Action

How Uric Works

This section explains the mechanism of action of the active ingredient, Allopurinol, focusing on its molecular targets, the pathways it affects, and the resulting physiological changes.


Targeted Inhibition of Xanthine Oxidase

The drug functions by directly inhibiting the enzyme Xanthine Oxidase (XO), the biological target responsible for the final steps of purine catabolism. Both Allopurinol and its active, long-lasting metabolite, Oxypurinol, bind to the enzyme, functionally shutting down its ability to convert purine precursors into Uric Acid.


Modulation of Purine Metabolism

By blocking Xanthine Oxidase, the drug interrupts the natural flow of the metabolic process. This causes the body to accumulate the purine precursors, Hypoxanthine and Xanthine, instead of synthesizing Uric Acid. These precursors are significantly more soluble than Uric Acid itself, leading to their efficient renal clearance.


Systemic Uric Acid Source Reduction

This mechanism is classified as uricostatic because its entire action is dedicated to suppressing the synthesis (source) of Uric Acid throughout the body. The resulting physiological effect is a sustained and progressive reduction in the concentration of serum urate, which contributes to a sustained physiological change by lowering the overall systemic urate load.

Dosage and Administration Information

The administration of Uric, whose active ingredient is allopurinol, is governed by a standardized protocol focused on long-term management of serum uric acid levels. The medicine is primarily available as an oral tablet in 100 mg and 300 mg strengths, though an intravenous form is approved for use in specific clinical settings.

Dosing and Titration

Oral tablets must be taken with or immediately after food to mitigate potential gastrointestinal irritation. The dosing regimen for chronic conditions typically begins with a low starting dose, such as 100 mg once daily for adults with normal kidney function. The dose is then gradually increased, often in 100 mg increments at weekly intervals, until the serum uric acid level reaches a therapeutic goal of 6 mg/dL or less. The maximum recommended dose is generally 800 mg per day. When the total daily dose exceeds 300 mg, the dose is typically administered in divided portions for improved tolerability.

Administration Requirements

Administration requires careful procedural adherence, including dose adjustments for patients with impaired kidney function, with the initial oral dose potentially reduced to 50 mg daily. For pediatric patients with hyperuricemia related to cancer therapy, the dosing is calculated based on body surface area. Furthermore, adequate fluid intake is a crucial component of the protocol, with the goal of maintaining a daily urinary output of at least two liters. If a scheduled dose is missed, instructions generally advise against taking a double dose at the next scheduled time. The overall use protocol establishes a structured, controlled approach to the medicine's long-term administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uric

Research on Uric (allopurinol) has primarily focused on studies evaluating conditions characterized by elevated uric acid levels. The evidence base consists mainly of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that evaluate changes in blood chemistry and outcomes reflecting daily functioning or activity level. Research does not determine whether an individual will respond similarly, but rather describes group patterns observed in the studies.


Evidence for Use in Chronic Gout and Hyperuricemia

The most extensive research for Uric has been conducted in conditions characterized by fluctuating or episodic manifestations related to chronic gout. Studies was studied for use in research contexts involving fluctuating or unstable symptoms of hyperuricemia.

Researchers used short- and medium-term RCTs to measure outcomes related to systemic or functional imbalance. Specifically, studies research examined whether measured changes in serum urate (SUA) concentration occurred and whether specific target levels were achieved. Findings describe patterns observed in the studies where participants receiving the medicine showed measured differences in SUA levels compared to control groups.

Longer-term research studies explored outcomes related to physical discomfort and conditions marked by functional limitations. Studies observed outcomes related to physical discomfort, including the frequency of acute gout flares and changes in the size of tophus deposits. Research highlights changes measured during the study period, with some trials describing patterns of reduction in the reported frequency of flares, particularly when observing responses over defined time intervals spanning many months.

Evidence for Use in Acute Uric Acid Control During Cancer Treatment

Research has also explored the use of Uric in specialized acute settings, focusing on episodes where symptoms become more noticeable due to temporary physiological imbalance. These studies were conducted as Randomized Comparative Trials or Prospective Cohort Studies during specific high-risk periods—namely, the use of certain cancer therapies that can lead to rapid cell breakdown and a sudden, acute elevation of uric acid.

In this context, research examined temporary physiological imbalance, with study outcomes primarily linked to inflammatory or irritative states. Studies monitored the rate of achieving and maintaining non-elevated uric acid levels in the plasma, alongside recording the incidence of acute complications like kidney injury. Research provides insight into short-term changes and studies contribute to the broader evidence landscape regarding outcomes related to the management of uric acid in these high-risk populations, which included both adult and pediatric patients with certain types of malignancies.

Evidence for Use in Kidney Stone Prevention

A smaller body of research, including some Randomized Controlled Trials and clinical guidance reviews, has explored the use of Uric in conditions associated with acute or disruptive episodes: the recurrence of certain calcium oxalate kidney stones. This research focused on specific populations of adults who had both a history of stone formation and hyperuricosuria (excess uric acid in the urine).

Studies explored outcomes monitoring physiological strain or stress, particularly measuring the reduction in urinary uric acid excretion. Trials studies explored outcomes describing episodic or acute changes, including the rate of recurrence of new kidney stones, with observation periods often lasting multiple years. Findings describe patterns observed in these studies where individuals showed measured changes in uric acid excretion and, in some cases, data show patterns related to a lowered frequency of new stone episodes.


Long-Term Evidence and Durability of Response

Research has attempted to understand the durability of response and long-term outcomes, particularly for chronic gout. While short- and medium-term studies are numerous, there is limited information for long-term outcomes that track sustained use over many years. Follow-up durations were limited in many initial registration trials.

Available evidence contributes to the broader evidence landscape by noting that the measured changes in SUA concentration appears to be maintained over defined time intervals. However, comprehensive, long-term data for clinical endpoints, such as the total prevention of functional limitations or the complete dissolution of all tophi, are not fully established.

Evidence in Specific Patient Groups and Comorbidities

Studies have also monitored the use of Uric in specific subgroups, notably in patients with concurrent Chronic Kidney Disease (CKD). Research examined temporary physiological imbalance and tracked outcomes in adults with varying degrees of CKD severity. However, data for certain groups remain insufficient, particularly those with more advanced kidney disease, to fully characterize long-term management strategies. Research in children receiving chemotherapy is available, but data for other pediatric applications are still emerging.

Key Evidence Gaps and Areas of Research Uncertainty

Research is ongoing, and findings provide context but not individual predictions. The evidence highlights what is known — and what is still uncertain.

One key area where findings were mixed involves research exploring outcomes related to physical discomfort. Specifically, results from large, contemporary studies examining whether Uric provides direct benefits for cardiovascular death or the progression of Chronic Kidney Disease (CKD) does not determine whether an individual will respond similarly regarding these specific long-term outcomes.

Furthermore, evidence quality varies across studies, and sample sizes were modest for some of the less common indications, meaning results apply only to the populations studied and cannot be assumed to apply broadly to all conditions.

Frequently Asked Questions (FAQ)

Common questions about Uric (FAQ)


Q: Is Uric the same type of medicine as allopurinol?

A: Uric is a brand name for the active pharmaceutical ingredient allopurinol. Regulatory documents identify the medicine’s core component as allopurinol, which functions as a uric acid reducer.


Q: What ingredients are in Uric besides the main active component?

A: Official product information, such as prescribing labels, lists the active ingredient, allopurinol, as well as several inactive ingredients (sometimes called excipients). These inactive ingredients are used to form the tablet.


Q: How quickly does Uric start to work?

A: The medicine generally begins to reduce serum uric acid levels within two to three days of starting treatment. Official guidance indicates that a week or more of consistent use may be necessary before the full effects are typically observed in the body.


Q: How long do I need to take Uric?

A: Uric is generally prescribed as a long-term maintenance approach for chronic conditions. Treatment duration is determined by a healthcare provider and depends on the specific therapeutic goals.


Q: Can Uric affect my sleep?

A: Regulatory documentation lists effects on the central nervous system, such as drowsiness and somnolence (excessive sleepiness), among the reported adverse reactions. These effects may be an indication that the medicine is affecting mental state.


Q: What happens if I miss a dose of Uric?

A: Regulatory guidance describes that if a dose is missed, patients should follow the specific protocol provided by their healthcare professional. However, it is strictly stated in official instructions that a double dose should never be taken to make up for a missed dose.


Q: Can Uric be taken with ibuprofen or Tylenol?

A: Official drug information generally describes that the active ingredient, allopurinol, can be taken alongside common over-the-counter pain relievers such as acetaminophen (Tylenol) and ibuprofen. It is generally described that co-administration should be discussed with a healthcare provider.


Q: Does Uric cause weight gain?

A: Weight gain is not typically listed as a common adverse reaction in official product documentation. Some rare, serious side effect reports have, conversely, included occurrences of weight loss.


Q: Is it normal to feel tired when starting Uric?

A: Official documentation indicates that feelings of unusual drowsiness, dullness, or weakness/tiredness, as well as severe sleepiness, are among the documented adverse events reported in clinical data.


Q: Does Uric interact with common vitamins or supplements?

A: Regulatory guidance often states that there is not enough specific evidence to fully determine the safety of using complementary medicines, herbal remedies, and supplements concurrently with the active ingredient.


Q: Are there any long-term effects of taking Uric?

A: The expected long-term effect is the sustained reduction of serum uric acid. Severe, but rare, long-term adverse effects reported in official documentation include changes in liver function or conditions affecting the bone marrow.


Q: Does Uric change how my body uses food or nutrients?

A: The medicine's function is strictly defined by its targeted action of interrupting the body’s purine catabolism. This is the specific metabolic process used by the body to break down purines derived from food and internal body processes into uric acid.


Q: Is Uric safe for someone who has liver problems?

A: Due to reported hepatotoxicity (liver injury), official guidance highlights the importance of patient evaluation. The prescribing protocol includes monitoring of liver function tests if there are signs of liver injury developing.


Q: Are there any known interactions between Uric and common cold medicine?

A: Regulatory documents mention that Uric may interact with certain ingredients commonly found in cold remedies, such as those that are sympathomimetic agents or cause sedation. This co-administration may lead to enhanced cardiovascular adverse effects or increased drowsiness.


Q: What is the difference between a side effect and an allergic reaction to Uric?

A: Official documents define side effects as a list of documented adverse reactions that may occur. Allergic reactions are described as severe hypersensitivity reactions, which regulatory documents state necessitate immediate and permanent discontinuation by a medical professional.


Q: Is Uric used for any conditions other than what is listed in the main uses?

A: The approved indications for the active ingredient include the management of gout, high uric acid levels due to certain cancer therapies, and the management of recurrent calcium oxalate kidney stones in specific patient populations.


Q: How common are serious side effects with Uric?

A: Serious adverse reactions, such as the severe skin reactions SJS, TEN, and DRESS, are reported in official documentation to occur in approximately 5 out of every 10,000 patients taking the active ingredient. These events are classified as rare but serious and adverse.


Q: What if Uric doesn't seem to be working after a few weeks?

A: Regulatory guidance describes that the full effect of the medicine may require a week or more to manifest. If the therapeutic goal (target serum uric acid level) is not met, the official prescribing protocol details steps for a gradual dose adjustment.


Q: Can women who are planning pregnancy use Uric?

A: Official information indicates that the decision regarding use when planning pregnancy should be made with a healthcare provider. The medicine is not usually recommended during pregnancy due to limited safety data, and a doctor may recommend alternative treatments.


Q: Why do some people stop taking Uric?

A: Official labeling describes that the medicine should be stopped immediately and permanently if a severe skin rash or hypersensitivity reaction occurs. Treatment discontinuation for other reasons, such as efficacy or intolerance, is overseen by a doctor.


Q: Can I stop taking Uric when my symptoms improve?

A: Regulatory guidance describes that treatment for chronic conditions is long-term and that the decision to stop treatment is determined by a healthcare provider. Sudden cessation of maintenance therapy carries a documented risk of the underlying condition worsening.


Q: Does Uric affect fertility?

A: Official patient guidance indicates that there is no current evidence to suggest that taking the active ingredient reduces fertility in either men or women.


Q: Can Uric cause headaches?

A: Yes, regulatory documentation confirms that headache is among the adverse effects that have been reported by individuals taking the active ingredient.


Q: What should I do if I feel dizzy after taking Uric?

A: Official documents report dizziness as a possible adverse effect. Due to the potential for dizziness, official documents advise caution when performing tasks such as driving or operating complex machinery. Such effects are typically reported to a healthcare provider.


Q: Is Uric a once-a-day medicine?

A: The starting dose is typically given once a day. However, official prescribing information advises that if the total daily dose is increased above a certain amount, the dose may be administered in divided portions throughout the day.


Q: Does the time of day matter when taking Uric?

A: While the medicine can generally be taken at any time of the day, regulatory-based information advises patients to aim to take their dose at the same time each day to maintain consistency.


Q: Is it true that Uric can cause 'gout flares' when first started?

A: Yes, official documentation reports that gout flares may occur during the initiation of treatment. For this reason, concurrent prophylactic (preventive) treatment is often recommended during this initial period.


Q: What is the purpose of the laboratory tests needed before or during Uric use?

A: Tests are necessary to monitor serum uric acid levels to guide dose titration, check kidney function for dose adjustments, and monitor liver function and blood cell counts during ongoing treatment.


Q: Can Uric be taken with food, or does it have to be taken on an empty stomach?

A: Official prescribing instructions state that the tablets are typically administered with or immediately following food. This recommendation is given to help reduce the possibility of stomach irritation.


Q: How long does it take for Uric's effect to wear off after I stop taking it?

A: After the medicine is stopped, official information indicates that uric acid levels generally return to pretreatment levels slowly. This usually takes about 7 to 10 days, which reflects the long-lasting activity of the active metabolite, oxipurinol.

How should Uric be stored and disposed of?

Storage and Disposal Requirements for Uric (Allopurinol Tablets)

Detail Official Regulatory Requirement
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F); do not store above 25 C [Source: FDA/DailyMed, UK SmPC].
Protection and Container Store in a dry place in the original container and keep the container tightly closed to protect from moisture [Source: NIH MedlinePlus, UK SmPC].
Child Safety Keep out of the sight and reach of children [Source: NIH MedlinePlus].
Disposal Instructions Do not flush the product down the toilet or pour into a drain [Source: EMA SmPC, FDA]. Disposal must follow local regulations or utilize a drug take-back program [Source: EMA SmPC, FDA].

Official regulatory documents strictly define that Uric must be stored under Controlled Room Temperature conditions, protected from moisture and heat within its original, tightly closed container to ensure product stability. The label mandates that the medication be kept inaccessible to children. Disposal instructions prohibit discarding the product via drains, directing disposal through specific pharmaceutical waste procedures or authorized collection sites.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uric found in:

A-Z Index: